We first demonstrated the functions of AGTR1 in attenuating HCC cell senescence through ERK signaling, providing a novel potential target as well as a potential combination therapy of AGTR1 suppression with sorafenib for HCC. This evidence concerns the gene AGTR1 and hepatocellular carcinoma.